Study: Weight-loss drug Wegovy cuts heart attack risk in those with obesity

  • 📰 washingtonpost
  • ⏱ Reading Time:
  • 35 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 72%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

The weight-loss drug Wegovy reduced the risk of strokes, heart attacks and other cardiovascular problems by 20 percent among overweight people with a history of heart disease, its manufacturer said Tuesday.

such as Wegovy, can provide important health benefits, not just cosmetic ones. Obesity should be treated as a serious illness given its contribution to other problems such as heart disease, specialists said.Wegovy, and Medicare is barred from paying for weight-loss medications. With Wegovy costing more than $1,300 a month, the lack of insurance coverage has put the drug out of reach for many people.

Steven Nissen, a Cleveland Clinic cardiologist, noted that while Tuesday’s announcement is promising, he wants to see the full results. Ozempic is approved by the Food and Drug Administration for treating Type 2 diabetes, although doctors commonly prescribe it for weight loss.Mounjaro, which is also called tirzepatide, mimics GLP-1 but also targets a second, closely related hormone called GIP, which also stimulates insulin production. Lilly is seeking FDA approval to market Mounjaro to manage weight loss as well as diabetes.

Martin Holst Lange, executive vice president for development at Novo Nordisk, called the Select trial a “landmark study” in the company’s statement.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 95. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Source: Reuters - 🏆 2. / 97 Read more »

Novo weight-loss drug Wegovy shows heart benefit in trialNovo Nordisk announced that a trial has revealed that patients taking the weight-loss drug Wegovy had a 20% lower risk of heart attack, stroke, or death from heart disease compared to those on a placebo. This finding gives hope to Novo Nordisk in expanding the perception of Wegovy beyond being just a lifestyle drug.
Source: nypost - 🏆 91. / 67 Read more »

Wegovy Reduces Risk of Heart Attack and Stroke in Major Cardiovascular TrialA major clinical trial has shown that the weight loss drug Wegovy can reduce the risk of heart attack, stroke, or heart disease-related death by 20% in people with cardiovascular disease, marking the first time a weight loss drug has demonstrated such protective effects.
Source: CNN - 🏆 4. / 95 Read more »